J. Vos

发表

Inverse birth cohort effects in ovarian cancer: Increasing risk in BRCA1/2 mutation carriers and decreasing risk in the general population.

J. Oosterwijk, G. D. de Bock, M. Mourits, 2016, Gynecologic oncology.

Variation in Mutation Spectrum Partly Explains Regional Differences in the Breast Cancer Risk of Female BRCA Mutation Carriers in the Netherlands

H. Meijers-Heijboer, C. V. van Asperen, J. Oosterwijk, 2014, Cancer Epidemiology, Biomarkers & Prevention.

Cancer risk variation in BRCA1/2 mutation families

J. Oosterwijk, G. D. de Bock, J. Vos, 2016 .

Boosting care and knowledge about hereditary cancer: European Reference Network on Genetic Tumour Risk Syndromes

E. Schröck, C. Lázaro, G. Capellá, 2018, Familial Cancer.

The yield and effectiveness of breast cancer surveillance in women with PTEN Hamartoma Tumor Syndrome

P. Bult, R. Mann, N. Hoogerbrugge, 2022, Cancer.

A review on age‐related cancer risks in PTEN hamartoma tumor syndrome

J. Schuurs-Hoeijmakers, N. Hoogerbrugge, J. Vos, 2020, Clinical genetics.

Evaluation of yield and experiences of age‐related molecular investigation for heritable and nonheritable causes of mismatch repair deficient colorectal cancer to identify Lynch syndrome

I. Nagtegaal, M. Ligtenberg, N. Hoogerbrugge, 2020, International journal of cancer.

Mutational Signature Analysis Reveals NTHL1 Deficiency to Cause a Multi-tumor Phenotype.

W. Foulkes, G. Capellá, I. Tomlinson, 2019, Cancer cell.

The association between cancer family history and ovarian cancer risk in BRCA1/2 mutation carriers: can it be explained by the mutation position?

P. Devilee, H. Meijers-Heijboer, M. Kriege, 2018, European Journal of Human Genetics.

The association between family history of cancer and ovarian cancer risk in BRCA1/2 mutation carriers: can it be explained completely by the mutation position on the gene? Submitted for publication

H. Meijers-Heijboer, R. B. Luijt, M. Kriege, 2017 .

Red flags for early recognition of adult patients with PTEN Hamartoma Tumour Syndrome.

J. Schuurs-Hoeijmakers, N. Hoogerbrugge, J. Schieving, 2021, European journal of medical genetics.

Bias Correction Methods Explain Much of the Variation Seen in Breast Cancer Risks of BRCA1/2 Mutation Carriers.

J. Oosterwijk, K. Malone, G. D. de Bock, 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Genotype-phenotype associations in a large PTEN Hamartoma Tumor Syndrome (PHTS) patient cohort.

J. Schuurs-Hoeijmakers, M. Genuardi, T. Kleefstra, 2022, European journal of medical genetics.

Detection and Yield of Colorectal Cancer Surveillance in Adults with PTEN Hamartoma Tumour Syndrome

I. Nagtegaal, N. Hoogerbrugge, M. V. van Kouwen, 2022, Cancers.

Cancer Surveillance Guideline for individuals with PTEN hamartoma tumour syndrome

E. Schröck, C. Lázaro, G. Capellá, 2020, European Journal of Human Genetics.

The impact of mutation position on the gene and family history on ovarian cancer risk in BRCA1/2 mutation carriers

J. Oosterwijk, G. H. Bock, M. Mourits, 2015 .

Universal Tumor DNA BRCA1/2 Testing of Ovarian Cancer: Prescreening PARPi Treatment and Genetic Predisposition

M. C. Vos, I. Nagtegaal, L. Kooreman, 2019, Journal of the National Cancer Institute.

Probability of detecting germline BRCA1/2 pathogenic variants in histological subtypes of ovarian carcinoma. A meta-analysis.

Vera M Witjes, T. Bosse, M. Ausems, 2021, Gynecologic oncology.

Ovarian cancer in BRCA1/2 mutation carriers: The impact of mutation position and family history on the cancer risk.

J. Oosterwijk, G. H. Bock, M. Mourits, 2015, Maturitas.

Parelsnoer Institute Biobank Hereditary Colorectal Cancer: A Joint Infrastructure for Patient Data and Biomaterial on Hereditary Colorectal Cancer in the Netherlands

E. Dekker, W. Mesker, P. Manders, 2019, Open Journal of Bioresources.

Relevance and efficacy of breast cancer screening in BRCA1 and BRCA2 mutation carriers above 60 years: A national cohort study

H. Meijers-Heijboer, M. Hooning, C. Seynaeve, 2014, International journal of cancer.

Cancer risks by sex and variant type in PTEN Hamartoma Tumor Syndrome.

J. Schuurs-Hoeijmakers, C. Houdayer, S. Aretz, 2022, Journal of the National Cancer Institute.

Bias Explains Most of the Parent-of-Origin Effect on Breast Cancer Risk in BRCA1/2 Mutation Carriers

M. Adank, A. Jager, C. V. van Asperen, 2016, Cancer Epidemiology, Biomarkers & Prevention.

Yield of annual endometrial cancer surveillance in women with PTEN Hamartoma Tumor Syndrome.

A. V. van Altena, N. Hoogerbrugge, J. D. de Hullu, 2023, European journal of medical genetics.

The most efficient and effective BRCA1/2 testing strategy in epithelial ovarian cancer: Tumor-First or Germline-First?

E. Adang, M. Ausems, N. Hoogerbrugge, 2023, Gynecologic oncology.

Universal genetic assessment for women with ovarian cancer not yet achieved: The promises of universal tumor DNA testing

N. Hoogerbrugge, J. Vos, M. Ligtenberg, 2021, Gynecologic oncology reports.

Proven non-carriers in BRCA families have an earlier age of onset of breast cancer.

J. Oosterwijk, G. D. de Bock, M. Mourits, 2013, European journal of cancer.

Microsatellite instability in noncolorectal and nonendometrial malignancies in patients with Lynch syndrome

I. Nagtegaal, N. Hoogerbrugge, A. Mensenkamp, 2023, Journal of the National Cancer Institute.